Stockscreener 앱 받기
5.45
1.62%
-0.09
시장 영업 전:
5.45
전일 마감가:
$5.54
열려 있는:
$5.43
하루 거래량:
15,147
Relative Volume:
0.05
시가총액:
$61.47M
수익:
$800.00K
순이익/손실:
$-45.07M
주가수익비율:
-1.0365
EPS:
-5.2583
순현금흐름:
$-52.08M
1주 성능:
-1.80%
1개월 성능:
-4.05%
6개월 성능:
-12.80%
1년 성능:
+0.00%
1일 변동 폭
$5.42
$5.72
1주일 범위
$5.42
$5.92
52주 변동 폭
$3.94
$17.96
Imagenebio Inc Stock (IMA) Company Profile
명칭
Imagenebio Inc
전화
857-343-8292
주소
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.45 | 62.49M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 재개 | Wedbush | Underperform |
| 2025-10-24 | 개시 | Leerink Partners | Outperform |
Imagenebio Inc 주식(IMA)의 최신 뉴스
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
ImageneBio Inc. (IMA) Slips 1.58% as Stock Nears Critical Support LevelTRIN Signal - newsline.com
IMA Q1 2026 Earnings: Wider-than-expected loss as EPS misses estimatesOne-Time Loss Impact - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing R&D InvestmentsDividend Earnings Report - newsline.com
Ikena Oncology Inc stock (US4517401090): trading in United States halted as ImageneBio merger progre - AD HOC NEWS
Imagenebio Inc. Live Share Prices and Trades. IMA.US Live Streaming Share Prices. - London South East
ImageneBio Inc. (IMA) Seeks Footing Near Support After Minor DeclineTick Index - newsline.com
ImageneBio CEO to present at 2026 Jefferies Global Healthcare Conference in New York - Pluang
ImageneBio CEO to speak at New York Jefferies healthcare conference June 4 - Stock Titan
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally? - MSN
ImageneBio (IMA) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineCommunity Breakout Alerts - Newser
ImageneBio (IMA) Q1 2026 Results Fall Short — EPS $-0.95, Revenue $N/AExpert Stock Picks - Newser
ImageneBio (IMA) Q1 2026 Stumbles — EPS $-0.95 Misses TargetReturn On Assets - Newser
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio $30 million private placement ignites stock - MSN
BVF-affiliated entities hold up to 1.11M shares in ImageneBio (IMA) - Stock Titan
ImageneBio stock jumps on $30M financing - MSN
Blue Owl Capital (IMA) reports 959,337 shares, 8.51% stake in ImageneBio - Stock Titan
Why ImageneBio (IMA) could be the anchor your portfolio needs (Tick Up) 2026-05-11Earnings Breakout - Newser
Wedbush Reiterates Underperform Rating for ImageneBio (NASDAQ:IMA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), ImageneBio (IMA) and Natera (NTRA) - The Globe and Mail
Leerink Partners Maintains ImageneBio(IMA.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
William Blair Maintains ImageneBio(IMA.US) With Buy Rating - Moomoo
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update - The Manila Times
IMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
2.5M shares for resale by selling holders — ImageneBio (NASDAQ: IMA) - Stock Titan
ImageneBio reports Q1 2026 net loss of $10.6M, $117.2M cash on hand after $30M private placement - TradingView
ImageneBio (NASDAQ: IMA) posts larger Q1 loss but holds $117M cash - Stock Titan
ImageneBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ImageneBio (Nasdaq: IMA) Q1 2026 loss and OX40 program update - Stock Titan
With $30M raised, ImageneBio plans 2026 Phase 2 hair-loss study - Stock Titan
ImageneBio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
IMA SEC FilingsImageneBio 10-K, 10-Q, 8-K Forms - Stock Titan
IMA Price Today: ImageneBio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote - Stock Titan
[ARS] ImageneBio, Inc. SEC Filing - Stock Titan
OrbiMed adds pre-funded warrants in ImageneBio (IMA) 2026 PIPE - Stock Titan
IMA (ImageneBio) shares rise 2.42% after posting a narrower than expected Q4 2025 loss.Shared Buy Zones - newser.com
Imagenebio Inc (IMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Imagenebio Inc 주식 (IMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bonita David P | Director |
Jul 25 '25 |
Buy |
29.90 |
83,611 |
2,499,969 |
287,885 |
| Stampacchia Otello | Director |
Jul 25 '25 |
Buy |
29.90 |
267,556 |
7,999,924 |
454,982 |
1.27%
1.43%
자본화:
|
볼륨(24시간):